Overview

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Status:
Terminated

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.

Phase:

Phase 3

Details

Lead Sponsor:

Cell Genesys

Treatments:

Docetaxel
Hormones
Prednisone
Vaccines